mRNA-1403
- Generic Name
- mRNA-1403
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
Phase 3
Recruiting
- Conditions
- Acute GastroenteritisNorovirus Acute Gastroenteritis
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 25000
- Registration Number
- NCT06592794
- Locations
- 🇨🇦
Centricity Research Mirabel, Mirabel, Canada
🇺🇸Accel Research Sites - Achieve Clinical Research, Birmingham, Alabama, United States
🇺🇸Cullman Clinical Trials, Cullman, Alabama, United States
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Phase 1
Active, not recruiting
- Conditions
- Norovirus Acute Gastroenteritis
- Interventions
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1285
- Registration Number
- NCT05992935
- Locations
- 🇺🇸
ARK Clinical Research, LLC, Long Beach, California, United States
🇺🇸Optimal Research, Peoria, Illinois, United States
🇺🇸Rochester Clinical Research, Inc, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath